ghk-cu tolerance downregulation desensitization receptor Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide Opposing regulation of Gig2 by – ghk-cu tolerance desensitization receptor downregulation

This product is intended for adults who wish to include BPC-157 as part of an overall wellness regimen and who understand its investigational status.*1-8

Studies have also indicated interactions with opioid pathways DSIP administration has been shown to modulate pain perception and has effects that can be partially blocked by opioid antagonists in some paradigms, suggesting opioidergic involvement in at least some of its actions

Any change in viscosity warrants suspicion

In addition, highly acidic environments and strong oxidizing systems can destabilize the peptide

NCT06534411 Disclaimer: This article is for informational and educational purposes only